Many studies aim to detect the early phase of dementia. One of the major ways to achieve
this is to identify corresponding biomarkers, particularly immune blood biomarkers. The …

Background and purpose Blood‐based biomarkers are promising tools for the diagnosis of
Alzheimer disease (AD) at prodromal stages (mild cognitive impairment [MCI]) and are …

Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct
relationship between comorbidities and neurodegeneration. In this study, immunomagnetic …

Objectives: To investigate the relationships between episodic memory, APOE genotype,
CSF markers (total tau, T-tau; phospho-tau, P-tau; β-amyloid, Aβ42) and longitudinal …

APOE‑ε4 genotype (apolipoprotein E, epsilon 4) is the strongest genetic risk factor for
Alzheimer's disease (AD). Despite years of research, it is still not known how it contributes to …

Background: Neuroinflammatory cytokines can play a pivotal role in Alzheimer's disease
(AD) contributing to the evolution of degenerative processes. Objective: We aimed at …

OBJECTIVE: The aim of this study was to demonstrate the involvement of the inflammatory
proteins IL-6, ACT and CRP early in the pathology process of AD in patients with mild …

Background: Current treatment in Alzheimer's disease (AD) is initiated at a stage where the
brain already has irreversible structural deteriorations. Therefore, the concept of treatment …

In this report we evaluated the clinical performance of APOE genotyping and three protein
biomarkers (total tau, β-amyloid1–42, and tau phosphorylated at threonine 181) in a …

Dementia is a growing public health concern because of the lack of effective curative
treatment options and a rising global prevalence. Alzheimer's disease (AD) is the most …